ZHENG CHEN: Open Payments
NPI 1669878807 · LANHAM, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,172 in 177 payments from 21 companies in 2025. Trend: 2023 $805 · 2024 $1,705 · 2025 $4,172
Food & beverage: $4,172
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 25 | $785 |
| ABBVIE INC. | 19 | $579 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $500 |
| PFIZER INC. | 30 | $488 |
| Madrigal Pharmaceuticals | 15 | $437 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $257 |
| Ardelyx, Inc. | 8 | $252 |
| Gilead Sciences, Inc. | 3 | $145 |
| Celltrion USA Inc. | 14 | $141 |
| GENZYME CORPORATION | 4 | $93 |
Products named: TREMFYA, REZDIFFRA, ENTYVIO, VELSIPITY, XIFAXAN, IBSRELA, CREON, XELJANZ.
Industry payments across MD — which companies pay providers there.
